Finoriq research workspace
Aurinia Pharmaceuticals Inc. (AUPH) Institutional Holdings & 13F Ownership
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to. Review AUPH institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
- Company
- Aurinia Pharmaceuticals Inc. (AUPH)
- Ticker
- AUPH
- Market Cap
- $2B
- Latest Price
- $15.36
- Industry
- Biotech & Pharma
Aurinia Pharmaceuticals Inc. (AUPH) Top Institutional Holders
Top current 13F holders indexed for Aurinia Pharmaceuticals Inc. (AUPH). Latest period 2026-03-31.
| Rank | Investor | Value | Portfolio | Filing |
|---|---|---|---|---|
| 1 | Joel GreenblattCIK 0001510387 | $2.5M | 0.01% | Filing2026-05-15 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.